The 6th Annual T-cell Lymphoma Forum took place January 23-25, 2014, in San Francisco, California.

Allo-SCT can be effective in advanced SS, MF



HSCs_being_prepared_for_transplant_credit_Chad_McNeeley_230.jpg
SCT preparation
Credit: Chad McNeeley

A single-center study suggests that transplant can induce remissions and improve survival in certain patients with advanced cutaneous T-cell lymphomas. Allogeneic stem cell transplant (SCT) proved particularly effective in patients with Sézary syndrome (SS). It also conferred benefits to mycosis fungoides (MF) patients with large-cell transformation (LCT), but patients... [Read Article]

Consortium study falls short of expectations



Advani_Ranjana_MD_larryyoungphotos_230_v2.jpg
Ranjana Advani, MD
larryyoungphotos.com

A group’s effort to identify optimal front-line treatment for peripheral T-cell lymphomas (PTCLs) was not as successful as researchers anticipated. The North American PTCL Consortium set out to find a treatment that could best CHOP, as studies have suggested this regimen is inadequate for patients with PTCL. So... [Read Article]

Regimen shows promise for ENKTL



Huang_Huiqiang_larryyoungphotos_230.jpg
Hui-qiang Huang, MD, PhD
larryyoungphotos.com

Results of a single-center study suggest that a 3-drug regimen may be a safe and effective treatment option for patients with newly diagnosed or relapsed/refractory extranodal natural killer/T-cell lymphoma (ENKTL). The combination of pegaspargase, gemcitabine, and oxaliplatin (P-Gemox) elicited a high rate of response in this cohort... [Read Article]

TNFRII may play key role in CTCL, speaker says



Ungewickell_Alex_larryyoungphotos_220.jpg
Dr Alexander Ungewickell
larryyoungphotos.com

Researchers have found evidence to suggest that tumor necrosis factor receptor II (TNFRII) may be an important driver of cutaneous T-cell lymphomas (CTCLs). The team discovered that a mutation in this receptor—TNFRII T377I—is present in patients with mycosis fungoides (MF) and those with Sézary syndrome (SS). And previous... [Read Article]

Inhibitor appears active in relapsed/refractory TCLs



TCLF_2104_poster_reception_larryyoungphotos_220_v2.jpg
Attendees peruse posters
at TCLF 2014
larryyoungphotos.com

Preliminary results of a phase 1 trial suggest the PI3K-delta/gamma inhibitor IPI-145 is active in patients with relapsed or refractory T-cell lymphomas. Among 26 evaluable patients, 9 experienced partial responses to treatment with IPI-145, and 1 achieved a complete response, for an overall response... [Read Article]

A new prognostic model for PTCL?



Petrich_Adam_MD_larryyoungphotoscom_230.jpg
Adam Petrich, MD
larryyoungphotos.com

Unlike its predecessors, a new prognostic model suggests race and histology are important predictors of outcome in patients with peripheral T-cell lymphoma (PTCL). Researchers analyzed nearly 9000 patients diagnosed with PTCL in the US and found evidence to suggest that patient age and race, as well as histology... [Read Article]